{"nctId":"NCT00661388","briefTitle":"A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.","startDateStruct":{"date":"2008-08"},"conditions":["Anemia"],"count":75,"armGroups":[{"label":"Continuous erythropoietin receptor activator (C.E.R.A.)","type":"EXPERIMENTAL","interventionNames":["Drug: methoxy polyethylene glycol-epoetin beta [Mircera]"]}],"interventions":[{"name":"methoxy polyethylene glycol-epoetin beta [Mircera]","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients, \\>=18 years of age;\n* chronic renal anemia;\n* predialysis stage;\n* no ESA therapy during previous 3 months.\n\nExclusion Criteria:\n\n* transfusion of red blood cells during previous 2 months;\n* poorly controlled hypertension requiring hospitalization in previous 6 months;\n* significant acute or chronic bleeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change in Hb Concentration Between Baseline and the Efficacy Evaluation Period","description":"Mean change in Hb concentration was calculated as the difference between the time adjusted average of Hb during the efficacy evaluation period (EEP \\[Week 29 to Week 36\\]), and the Hb at Baseline (Week 0). A positive change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":"0.74"}]}]}]},{"type":"SECONDARY","title":"Mean Time to Achievement of Response During the EEP","description":"Participants with Hb concentrations within target range of 10-12 g/dl were considered to be responders. Mean time to achievement of response during the EEP (Week 29 to Week 36) is presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":"20.96"}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants Whose Hb Concentrations Remained Within the Target Range of 10.0- 12.0 g/dLThroughout the EEP","description":"The percentage of participants whose Hb Concentrations remained within the target range of 10.0- 12.0 g/dL throughout the EEP (Week 29 to Week 36) is presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Time Spent by Participants in the Target Range of 10.0- 12.0 g/dL During the EEP","description":"Mean time spent by participants in the target range of 10.0- 12.0 g/dL during the EEP (Week 29 to Week 36) is presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.6","spread":"16.31"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Requiring Dose Adjustments During Dose Titration Period and EEP","description":"Percentage of participants requiring dose adjustments during dose titration period (DTP \\[Week 0 to Week 28\\]) and EEP (Week 29 to Week 36) is presented. The dose adjustments (increase or decrease) were required: if a single Hb concentration was either ≥ 13 g/dL or \\< 9 g/dL; if the difference of 2 consecutive Hb concentrations was ≥2 g/dL; if the values of scheduled Hb assessments on the day of administration of C.E.R.A. and on the previous study visit were both out of range of 10 to 12 g/dL; if the values of the scheduled Hb assessments on the day of administration of C.E.R.A. and on the previous study visit were both out of the range 10.5 to 11.5 g/dL. Dose adjustment could be made at any time at the discretion of the clinician if clinically warranted.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Received Red Blood Cell Transfusions During the Study Period","description":"Red blood cell transfusions were given during the treatment period in case of medical need. Blood transfusions occurred during the DTP (Week 0 to Week 28), EEP (Week 29 to Week 36), and during the long term safety period (LSTP \\[Week 37 to Week 52\\]) are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Experienced Any Adverse Events or Serious Adverse Events","description":"An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Hb Concentration Over Time","description":"Mean change from Baseline in Hb concentration was calculated as the difference between Baseline and post-baseline measurements. It was recorded for each participant at enrollment (Week 0) and at different time points during the study up to Week 48.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":"0.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.03","spread":"1.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.86","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.84","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.59","spread":"0.81"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Hematocrit Level Over Time","description":"Mean change from Baseline in hematocrit level was calculated as the difference between Baseline and post-baseline measurements. It was recorded for each participant at enrollment (Week 0) and at different time points during the study up to Week 48.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Erythrocyte Mean Corpuscular Volume Over Time","description":"Mean change from Baseline in erythrocyte mean corpuscular volume was calculated as the difference between Baseline and post-baseline measurements. It was recorded for each participant at enrollment (Week 0) and at different time points during the study up to Week 48.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"3.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.31","spread":"3.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.10","spread":"4.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":"4.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"3.67"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in White Blood Cells and Platelets Concentrations Over Time","description":"Mean change from Baseline in white blood cells (WBCs) and platelets concentrations was calculated as the difference between Baseline and post-baseline measurements. It was recorded for each participant at enrollment (Week 0) and at different time points during the study up to Week 48.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"1.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"1.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"1.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"1.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"1.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"1.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.39","spread":"52.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.73","spread":"46.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.55","spread":"41.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.34","spread":"47.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.84","spread":"46.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.40","spread":"40.74"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Albumin Concentration Over Time","description":"Mean change from Baseline in albumin concentration was calculated as the difference between Baseline and post-baseline measurements. It was recorded for each participant at enrollment (Week 0) and at different time points during the study up to Week 48.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":"3.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"3.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":"3.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"5.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.57","spread":"3.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.61","spread":"3.82"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in C-Reactive Protein Concentration Over Time","description":"Mean change from Baseline in C-Reactive Protein concentration was calculated as the difference between Baseline and post-baseline measurements. It was recorded for each participant at enrollment (Week 0) and at different time points during the study up to Week 48.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.82","spread":"13.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.80","spread":"13.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"9.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"9.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.49","spread":"4.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":"6.57"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Phosphate and Potassium Concentrations Over Time","description":"Mean change from Baseline in phosphate and potassium concentrations was calculated as the difference between Baseline and post-baseline measurements. It was recorded for each participant at enrollment (Week 0) and at different time points during the study up to Week 48.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.70"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Total Iron Binding Capacity and Iron Concentrations Over Time","description":"Mean change from Baseline in total iron binding capacity (TIBC) and iron concentrations was calculated as the difference between Baseline and post-baseline measurements. It was recorded for each participant at enrollment (Week 0) and at different time points during the study up to Week 48.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"10.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"8.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":"10.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"10.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.24","spread":"19.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.02","spread":"11.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.93","spread":"7.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"6.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.55","spread":"8.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":"8.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.64","spread":"6.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"9.24"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Creatinine Concentration Over Time","description":"Mean change from Baseline in creatinine concentration was calculated as the difference between Baseline and post-baseline measurements. It was recorded for each participant at enrollment (Week 0) and at different time points during the study up to Week 48.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Ferritin Concentration Over Time","description":"Mean change from Baseline in ferritin concentration was calculated as the difference between Baseline and post-baseline measurements. It was recorded for each participant at enrollment (Week 0) and at different time points during the study up to Week 48.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-95.15","spread":"86.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-82.82","spread":"115.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-71.98","spread":"131.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-78.45","spread":"121.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.94","spread":"141.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.46","spread":"146.58"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Transferrin Saturation Over Time","description":"Mean change from Baseline in transferrin saturation (TSAT) was calculated as the difference between Baseline and post-baseline measurements. It was recorded for each participant at enrollment (Week 0) and at different time points during the study up to Week 48.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.91","spread":"19.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.69","spread":"13.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.42","spread":"15.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.52","spread":"15.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.52","spread":"13.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.32","spread":"21.60"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":75},"commonTop":["Hypertension","Hyperkalaemia","Constipation","Nausea","Urinary tract infection"]}}}